BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25579717)

  • 1. Effects of Salacia oblonga on cardiovascular risk factors in chronic kidney disease patients: a prospective study.
    Singh RG; Rathore SS; Wani IA; ; Agrawal A; Dubey GP
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):61-6. PubMed ID: 25579717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephroprotective role of salacia chinensis in diabetic CKD patients: a pilot study.
    Singh RG; Rathore SS; Kumar R; ; Agarwal A; Dubey GP
    Indian J Med Sci; 2010 Aug; 64(8):378-84. PubMed ID: 22945782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Kidney Disease and Lipid Disorders.
    Zubovic SV; Kristic S; Prevljak S; Pasic IS
    Med Arch; 2016 Jun; 70(3):191-2. PubMed ID: 27594744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum C-reactive protein levels in pre-dialysis chronic kidney disease patientsin southern Nigeria.
    Adejumo OA; Okaka EI; Okwuonu CG; Iyawe IO; Odujoko OO
    Ghana Med J; 2016 Mar; 50(1):31-8. PubMed ID: 27605722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes.
    Williams JA; Choe YS; Noss MJ; Baumgartner CJ; Mustad VA
    Am J Clin Nutr; 2007 Jul; 86(1):124-30. PubMed ID: 17616771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Charytan DM; Lewis EF; Desai AS; Weinrauch LA; Ivanovich P; Toto RD; Claggett B; Liu J; Hartley LH; Finn P; Singh AK; Levey AS; Pfeffer MA; McMurray JJ; Solomon SD
    Am J Kidney Dis; 2015 Sep; 66(3):429-40. PubMed ID: 25935581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relation between serum testosterone levels and cardiovascular risk factors in patients with kidney transplantation and chronic kidney disease.
    Colak H; Sert I; Kurtulmus Y; Karaca C; Toz H; Kursat S
    Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):951-9. PubMed ID: 25193890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Znorko B; Mor AL; Mysliwiec M; Pawlak D
    Int Urol Nephrol; 2019 Mar; 51(3):491-502. PubMed ID: 30617956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.
    Yelken B; Caliskan Y; Gorgulu N; Altun I; Yilmaz A; Yazici H; Oflaz H; Yildiz A
    Clin Nephrol; 2012 Apr; 77(4):275-82. PubMed ID: 22445470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease.
    Goicoechea M; Quiroga B; García de Vinuesa S; Verdalles U; Reque J; Panizo N; Arroyo D; Santos A; Macías N; Luño J
    Ren Fail; 2012; 34(8):1002-9. PubMed ID: 22746155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
    Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
    Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of hepatic sterol regulatory element-binding protein-1c-mediated gene expression contributes to Salacia oblonga root-elicited improvement of fructose-induced fatty liver in rats.
    Liu L; Yang M; Lin X; Li Y; Liu C; Yang Y; Yamahara J; Wang J; Li Y
    J Ethnopharmacol; 2013 Dec; 150(3):1045-52. PubMed ID: 24157375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease.
    Lee BT; Ahmed FA; Hamm LL; Teran FJ; Chen CS; Liu Y; Shah K; Rifai N; Batuman V; Simon EE; He J; Chen J
    BMC Nephrol; 2015 May; 16():77. PubMed ID: 26025192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
    Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
    Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of an anti-inflammatory supplement in patients with chronic kidney disease.
    Moreillon JJ; Bowden RG; Deike E; Griggs J; Wilson R; Shelmadine B; Cooke M; Beaujean A
    J Complement Integr Med; 2013 Jul; 10():. PubMed ID: 23828329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
    Nguyen SV; Nakamura T; Uematsu M; Fujioka D; Watanabe K; Watanabe Y; Obata JE; Nakamura K; Kugiyama K
    J Cardiol; 2017 Mar; 69(3):529-535. PubMed ID: 27256217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus.
    Ashraf R; Aamir K; Shaikh AR; Ahmed T
    J Ayub Med Coll Abbottabad; 2005; 17(3):60-4. PubMed ID: 16320801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Eckardt KU; Kewalramani R; Levey AS; McMurray JJ; Parfrey P; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2016 Dec; 68(6):873-881. PubMed ID: 27646425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.